Back to Search Start Over

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.

Authors :
Macaluso, Fabio Salvatore
Principi, Mariabeatrice
Facciotti, Federica
Contaldo, Antonella
Todeschini, Alessia
Saibeni, Simone
Bezzio, Cristina
Castiglione, Fabiana
Nardone, Olga Maria
Spagnuolo, Rocco
Fantini, Massimo Claudio
Riguccio, Gaia
Caprioli, Flavio
Viganò, Chiara
Felice, Carla
Fiorino, Gionata
Correale, Carmen
Bodini, Giorgia
Milla, Monica
Scardino, Giulia
Source :
Digestive & Liver Disease; Feb2023, Vol. 55 Issue 2, p154-159, 6p
Publication Year :
2023

Abstract

Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) E ffectiveness and S afety of C OVID-19 V a ccine in P ati e nts with I nflammatory B owel D isease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258). [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15908658
Volume :
55
Issue :
2
Database :
Supplemental Index
Journal :
Digestive & Liver Disease
Publication Type :
Academic Journal
Accession number :
161171926
Full Text :
https://doi.org/10.1016/j.dld.2022.08.027